Answers are grounded in this paper and cite their sources.
Open-label trial shows ANX005 improves outcomes in patients with Huntington's Disease, indicating its potential for further study.
Overall, AEs with ANX005 administration were manageable, and most patients received all planned doses. Evidence of clinical improvement with ANX005 was observed in patients with higher baseline complement activity, supporting future study in patients with HD.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: